Lixte Biotechnology Holdings, Inc. is a clinical stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company’s drug product pipeline centers on inhibitors of protein phosphatase 2A designed to enhance cytotoxic agents radiation immune checkpoint blockers and other cancer therapies. Lixte Biotechnology Holdings, Inc. is also the majority shareholder of Liora Technologies Europe Ltd. which is pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers.

Lixte Biotechnology Holdings, Inc. has not yet commenced any revenue generating operations and does not have positive cash flow from operations. The company relies on stock based compensation for a substantial portion of employee and consultant compensation and depends on periodic access to equity capital to fund its operating requirements. Future revenue is expected to arise from licensing agreements partnership deals and product sales after obtaining regulatory approval for its therapeutic candidates.

Lixte Biotechnology Holdings, Inc. occupies an early stage position in the biopharmaceutical industry with a niche focus on protein phosphatase 2A inhibitors and proton therapy technology. The company competes with larger pharmaceutical firms and specialized biotechnology companies that are developing conventional chemotherapy immunotherapy and targeted cancer drugs. In the proton therapy arena Lixte faces competition from established manufacturers such as IBA Worldwide Varian Medical Systems Hitachi Mevion Medical Systems ProNova Solutions P Cure and Sumitomo Heavy Industries. Lixte Biotechnology Holdings, Inc. differentiates itself through its novel mechanism of action that enhances the efficacy of existing cancer treatments without adding significant toxicity. The company’s intellectual property portfolio includes numerous issued patents and pending applications covering LB 100 and its combinations with checkpoint inhibitors doxorubicin and other investigational compounds. Strategic collaborations with leading cancer centers such as MD Anderson Cancer Center the Netherlands Cancer Institute and the Spanish Sarcoma Group provide clinical validation and facilitate trial execution.

Lixte Biotechnology Holdings, Inc. does not currently generate revenue from product sales and therefore does not serve a commercial customer base. The company’s prospective customers include pharmaceutical companies seeking licensing partners for its LB 100 drug candidate biotechnology firms interested in co development arrangements cancer treatment centers that may adopt its proton therapy technology and hospitals that could become end users of its future therapeutic products.